Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders

Expert Opinion on Drug Safety

Volumn 7, Issue 4, 2008, Pages 435-445

  Bernardo, Carmina G ^a   Singh, Vivek ^a   Thompson, Peter M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aggression; Alzheimer's disease; Antidepressants; Anxiety; Atypical antipsychotics; Benzodiazepines; Carbamazepine; Delirium; Depression; Epilepsy; Mania; Post stroke; Psychosis; Seizures; Traumatic brain injury; Valproate

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; DEXAMPHETAMINE; DULOXETINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; METHYLPHENIDATE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OXAZEPAM; PERPHENAZINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

AGGRESSION; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ALZHEIMER DISEASE; ANOREXIA; ANTEROGRADE AMNESIA; ANTICHOLINERGIC SYNDROME; ANXIETY; ANXIETY DISORDER; APLASTIC ANEMIA; ATTENTION DISTURBANCE; AUTONOMIC DYSFUNCTION; BRONCHITIS; BRONCHOSPASM; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELIRIUM; DEPRESSION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEVER; GASTROINTESTINAL SYMPTOM; HEART CONDUCTION; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; INJURY; LIVER DYSFUNCTION; LOW DRUG DOSE; MANIA; MEMORY DISORDER; MENTAL DISEASE; NEPHROTOXICITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; QT PROLONGATION; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TRAUMATIC BRAIN INJURY; TREMOR; UNSTEADINESS; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA;

ALZHEIMER DISEASE; BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; EPILEPSY; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PSYCHOTROPIC DRUGS; STROKE;

EID: 48749097100     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.4.435     Document Type: Review

References (85)

1. Jana J, Hermann B, Barry J, et al. Clinical assessment of axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci 2005;17:172-9
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Text rev. (DSM IV-TR). Washington, DC: American Psychiatric Association, 2000
3. Lyketsos C, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002;52:243-52
4. Tune L. Management of noncognitive symptoms of dementia. In: Schatzberg A, Nemeroff C, editors, Textbook of psychopharmacology. Washington DC: American Psychiatric Publishing, Inc.; 2004. p. 935-48
5. Caballero J, Hitchcock M, Beversdorf D, et al. Long-term effects of antidepressants on cognition in patients with Alzheimer's disease. J Clin Pharm Ther 2006;31:593-8
6. Fridman E, Starkstein S. Treatment of depression in patients with dementia. CNS Drugs 2000;14:191-201
7. Stahl S. Essential psychopharmacology: neuroscientific basis and practical application. 2nd edition. New York: Cambridge University Press; 2000
8. Munro C, Brandt J, Sheppard J, et al. Cognitive response to pharmacological treatment for depression in Alzheimer's disease. Am J Geriatr Psychiatry 2004;12:491-8
9. Lyketsos C, Sheppard J, Steele C, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry 2000;157:1686-9
10. Lyketsos C, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737-46
11. Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997;2:231-9
12. Settle EC. Antidepressant drugs: disturbing and potentially dangerous side effects. J Clin Psychiatry 1998;59(Suppl 16):25-30
13. Tariot P, Loy R, Ryan J, et al. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002;54:1567-77
14. Bowden CL. Valproate. Bipolar Disord 2003;5:189-202
15. Porsteinsson A. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly. Drugs Aging 2006;23:877-86
16. Scharre D, Davis R, Warner J, et al. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer's disease. Am J Geriatr Psychiatry 2003;11:687-91
17. Lesser J, Hughes S. Psychosis, agitation and disinhibition in Alzheimer's disease: definitions and treatment options. Geriatrics 2006;61:14-20
18. Ballard C, Waite J, Birks J. A typical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD003476
19. Sink K, Holden K, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 2005;293:596-608
20. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004;65(Suppl 11):11-5
21. Schneider L, Tariot P, Dagerman K, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38
22. Desai A, Grossberg G. Diagnosis and treatment of Alzheimer's disease. Neurology 2005;64:S34-9
23. Cummings J. Drug therapy: Alzheimer's disease. N Engl J Med 2004;351:56-67
24. Pollock B, Mulsant B, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460-5
25. Porter V, Buxton W, Fairbanks L, et al. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. J Neuropsychiatry Clin Neurosci 2003;15:180-6
26. Rivas-Vazquez R, Carranza E, Rey G, et al. Alzheimer's disease: pharmacological treatment and management. Clinical Neuropsychol 2000; 14:93-109
27. Seitz D, Gill S, van Zyl L. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry 2007;68:11-21
28. Bhanushali M, Tuite P. The evaluation and management of patients with neuroloeptic malignant syndrome. Neurol Clin North Am 2004;22:389-411
29. American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. Am J Psychiatry 1999;156(Suppl 5):1-20
30. Lee H, Lyketsos C, Rao V. Pharmacological management of the psychiatric aspects of traumatic brain injury. Int Rev Psychiatry 2003;15:359-70
31. Maason F, Thicoipe M, Aye P, et al. Epidemiology of severe brain injuries: a prospective population-based study. J Trauma 2001;51:481-9
32. Zink BJ. Traumatic brain injury outcome: concepts for emergency care. Ann Emerg Med 2001;37:318-32
33. Okie S. Traumatic brain injury in the war zone. N Eng J Med 2005;352:2043-7
34. Warden D. Military TBI during the Iraq and Afghanistan wars. J Head Trauma Rehabil 2006;21:398-402
35. Silver JM, Yudofsky SC. Psychopharmacology. In: Silver JM, Yudofsky SC, Hales RE, editors, Neuropsychiatry of traumatic brain injury. Washington DC: American Psychiatric Press; 1994
36. Alderfer B, Arciniegas D, Silver J. Treatment of depression following traumatic brain injury. J Head Trauma Rehabil 2005;20:544-62
37. Fann J, Uomoto J, Katon W. Sertraline in the treatment of major depression following mild traumatic brain injury. J Neuropsychiatry Clin Neurosci 2000;12:226-32
38. Fann J, Uomoto J, Katon W. Cognitive improvement with treatment of depression following mild traumatic brain injury. Psychosomatics 2001;42:48-54
39. Teng C, Bhalerao S, Lee Z, et al. The use of bupropion in the treatment of restlessness after a traumatic brain injury. Brain Inj 2001;15:463-7
40. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety 1998;7:89-91
41. American Psychiatric Association. APA practice guidelines for the treatment of psychiatric disorders. Washington DC: American Psychiatric Association; 2006
42. Stoudemire A, Hill CD, Lewison BJ, et al. Lithium intolerance in a medical-psychiatric population. Gen Hosp Psychiatry 1998;20:85-90
43. Kadyan V, Mysiw W, Bogner J, et al. Gender differences in agitation after traumatic brain injury. Am J Phys Med Rehabil 2004;83:747-52
44. Chatham-Showalter PE, Kimmel DN. Agitated symptom response to divalproex following acute brain injury. J Neuropsychiatry Clin Neurosci 2000;12:395-7
45. Lombard LA, Zafonte RD. Agitation after traumatic brain injury. Am J Phys Med Rehabil 2005;84797-812
46. Pachet A, Friesen S, Winkelaar D, Gray S. Beneficial behavioural effects of lamotrigine in traumatic brain injury. Brain Inj 2003;17:715-22
47. Meythaler J, Depalma L, Devivo M, et al. Sertraline to improve arousal and alertness in severe traumatic brain injury. Brain Inj 2001;15:321-31
48. Fujii D, Ahmed I. Psychotic disorder following traumatic brain injury: a conceptual framework. Cognit Neuropsychiatry 2002;1:41-62
49. Davidson K, Bagley CR. Schizophrenia-like psychoses associated with organic disorders of the central nervous system: a review of the literature. Br J Psychiatry 1969;114:113-62
50. Cantor J, Ashman T, Schwartz M, et al. The role of self-discrepancy theory in understanding post-traumatic brain injury in affective disorders: a pilot study. J Head Trauma Rehabil 2005;20:527-43
51. Hiott D, Labbate L. Anxiety disorders associated with traumatic brain injuries. Neurorehabilitation 2002;17:345-55
52. Bourgeois J, Seritan A. Diagnosis and management of delirium. Continuum: Lifelong Learning in Neurology 2006;12(5):15-32
53. Starkstein S, Robinson R, Honig M, et al. Mood changes after right hemisphere lesions. Br J Psychiatry 1989;155:79-85
54. Astrom M, Adolfsson R, Asplund K. Major depression in stroke patients: A 3-year longitudinal study. Stroke 1993;24:976-82
55. Chemerinski E, Robinson R. The neuropsychiatry of stroke. Psychosomatics 2000;41:5-14
56. Goyal R, Sameer M, Chandrasekan R. Mania secondary to right-sided stroke - responsive to olanzapine. Gen Hosp Psychiatry 2006;28:262-3
57. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression. J Neurol 2003;250:347-51
58. Chen Y, Guo J, Zhan S, Patel N. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother 2006;40:2115-22
59. Orr K, Taylor D. Psychostimulants in the treatment of depression: a review of the evidence [abstract]. CNS Drugs 2007;21:239-57
60. Himelhoch S, Haller E. Extreme mood lability associated with systemic lupus sicosis asus and stroke successfully treated with valproic acid. J Clin Psychopharmacol 1996;16:469-70
61. Morris P, Robinson R, Raphael B, et al. Lesion location and post-stroke depression. J Neuropsychiatry Clin Neurosci 1996;8:399-403
62. Ramasubbu R. Lamotrigine treatment for post-stroke pathological laughing and crying. Clin Neuropharmacol 2003;26:233-5
63. Lampl Y, Lorberboym M, Gilad R, et al. Auditory hallucinations in acute stroke. Behav Neurol 2005;16:211-6
64. Skaisky A, Zhao H, Bourgeois J. Post-stroke psychosis in the acute inpatient rehabilitation setting: a case report [posterl. AAP Annual Meeting; 2 - 4 March 2006; Daytona Beach, FL
65. Ortiz N, Annoni J, Trojan D, et al. Persistent severe depressive episode with mood-congruent psychotic features associated with left temporal ischemia. Cogn Behav Neurol 2004;17:157-62
66. Chemerinski E, Levine S. Neuropsychiatric disorders following vascular brain injury. J Mt Sinai Hosp N Y 2006;73:1006-14
67. Ferro JM, Caeiro L, Verdelho A. Delirium in acute stroke. Curr Opin Neurol 2002;15:51-5
68. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004;110:207-20
69. Prueter C, Norra C. Mood disorders and their treatments in patients with epilepsy. J Neuropsychiatry Clin Neurosci 2005;17:20-8
70. Thome-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav 2007;10:417-25
71. Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004;27:133-6
72. Fakhoury TA, Barry JJ, Miller JM, et al. Lamotrigine in patients with epilepsy and comorbid depressive symptoms. Epilepsy Behav 2007;10:155-62
73. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001;2:28-36
74. Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav 2007;10:148-54
75. Schmitz B. Depression and mania in patients with epilepsy. Epilepsia 2005;46S:45-9
76. Mahgoub NA. A report of successful treatment of psychosis in epilepsy with risperidone. J Neuropsychiatry Clin Neurosci 2007;19:347-8
77. Herrero MS, Elvira LJ. Epileptic sicosis: a case report. Actas Esp Psiquiatr 2004;32:178-80
78. Alper KR, Barry JJ, Balabanov AJ. Treatment of psychosis, aggression and irritability in patients with epilepsy. Epilepsy Behav 2002;3:S13-8
79. Nadkarni S, Arnedo V, Devinsky O. Psychosis in epilepsy patients. Epilepsia 2007;48S:17-9
80. Brandt C, Fueratsch N, Boehme V, et al. Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of literature. Epilepsy Behav 2007;11:133-9
81. Mensah SA, Beavis JM, Thapar AK, Kerr MP. A community study of the presence of anxiety disorder in people with epilepsy. Epilepsy Behav 2007;11:118-24
82. Weintraub D, Stern M. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005;13:844-51
83. Sommer BR, Fenn HH, Ketter TA. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opin Drug Saf 2007;6:133-45
84. Stoudemire A, Beliles K. Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 1998;39:s2-19
85. Freeman MP, Freeman SA. Lithium: considerations in internal medicine. Am J Med 2006;119:478-81